2. Search Result
Search Result
Results for "

VGF

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

7

Peptides

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107760
    Decanoyl-RVKR-CMK
    1 Publications Verification

    DecRVKRcmk

    		 HIV Infection Inflammation/Immunology
    Decanoyl-RVKR-CMK (DecRVKRcmk) inhibits over-expressed gp160 processing and HIV-1 replication .
    Decanoyl-RVKR-CMK
  • HY-16728
    Rapastinel
    1 Publications Verification

    GLYX-13

    		 iGluR ERK mTOR Neurological Disease Cancer
    Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .
    Rapastinel
  • HY-107760A
    Decanoyl-RVKR-CMK TFA
    1 Publications Verification

    DecRVKRcmk TFA

    		 HIV Infection Inflammation/Immunology
    Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits over-expressed gp160 processing and HIV-1 replication .
    Decanoyl-RVKR-CMK TFA
  • HY-P1345A
    TLQP-21 TFA
    2 Publications Verification

    		 Complement System Neurological Disease Endocrinology
    TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca 2+. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .
    TLQP-21 TFA
  • HY-16728B
    Rapastinel Trifluoroacetate
    1 Publications Verification

    GLYX-13 Trifluoroacetate

    		 iGluR mTOR ERK Neurological Disease
    Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
    Rapastinel Trifluoroacetate
  • HY-P1345
    TLQP-21

    		Complement System Neurological Disease Endocrinology
    TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca 2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .
    TLQP-21
  • HY-RS17940
    Vgf Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Vgf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vgf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Vgf Mouse Pre-designed siRNA Set A
    Vgf Mouse Pre-designed siRNA Set A
  • HY-P11130
    LQEQ-19 (mouse, rat)

    		Akt ERK PI3K MEK Neurological Disease
    LQEQ-19 (mouse, rat) is a VGF derived peptide that exerts neuroprotective effects. LQEQ-19 (mouse, rat) activates the PI3K/Akt and MEK/ERK signaling pathways by promoting phosphorylation of Akt and ERK1/2. LQEQ-19 (mouse, rat) is commonly used in the study of neurological conditions .
    LQEQ-19 (mouse, rat)
  • HY-RS24411
    Vgf Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Vgf Rat Pre-designed siRNA Set A contains three designed siRNAs for Vgf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Vgf Rat Pre-designed siRNA Set A
    Vgf Rat Pre-designed siRNA Set A
  • HY-RS15643
    VGF Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    VGF Human Pre-designed siRNA Set A contains three designed siRNAs for VGF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    VGF Human Pre-designed siRNA Set A
    VGF Human Pre-designed siRNA Set A
  • HY-P11092
    TLQP-62 (mouse,rat)

    		Endogenous Metabolite Neurological Disease
    TLQP-62 (mouse,rat) is a secreted C-terminal peptide that can be derived from protein VGF. TLQP-62 activates the BDNF-TrkB signaling pathway, inducing acute, transient phosphorylation of TrkB receptor and downstream CREB (Ser133) phosphorylation. TLQP-62 demonstrates excellent efficacy in promoting long-term fear memory formationin wild-type mice and reversing memory impairment in VGF heterozygous knock-out mice. TLQP-62 can be used for the study of memory-related neurological disorders (e.g., Alzheimer’s disease, frontotemporal dementia) .
    TLQP-62 (mouse,rat)
  • HY-16728A
    Rapastinel acetate

    GLYX-13 acetate

    		 iGluR mTOR ERK Neurological Disease
    Rapastinel (GLYX-13) acetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel acetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel acetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel acetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
    Rapastinel acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: